BBA
RIGL icon

Baker Bros. Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Baker Bros. Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-104,161
Closed -$2.95M – 110
2018
Q2 		$2.95M Sell
104,161
-147,727
-59% -$5.26M 0.02% 93
2018
Q1 		$8.92M Hold
251,888
– – 0.08% 63
2017
Q4 		$9.8M Hold
251,888
– – 0.08% 58
2017
Q3 		$6.4M Hold
251,888
– – 0.05% 69
2017
Q2 		$6.88M Hold
251,888
– – 0.06% 56
2017
Q1 		$8.34M Buy
251,888
+50,000
+25% +$1.27M 0.07% 53
2016
Q4 		$4.8M Buy
+201,888
New +$5.78M 0.05% 65
2015
Q2 		– Sell
-35,719
Closed -$1.28M – 130
2015
Q1 		$1.28M Sell
35,719
-12,478
-26% -$342K 0.01% 116
2014
Q4 		$1.09M Hold
48,197
– – 0.01% 113
2014
Q3 		$935K Hold
48,197
– – 0.01% 98
2014
Q2 		$1.75M Hold
48,197
– – 0.02% 92
2014
Q1 		$1.87M Sell
48,197
-1,803
-4% -$64.3K 0.02% 89
2013
Q4 		$1.42M Hold
50,000
– – 0.02% 84
2013
Q3 		$1.79M Buy
+50,000
New +$1.82M 0.03% 72

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
OppenheimerFunds
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baker Bros. Advisors's RIGL Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q3 2018, closing a stake of 104,161 shares — an estimated $2.95M sold.

Baker Bros. Advisors first reported a position in RIGL in Q3 2013 and held it in 14 quarters. The position peaked at $9.8M in Q4 2017. 135 funds tracked by Wall St. Rank hold RIGL as of Q3 2018.

  • Baker Bros. Advisors reported no remaining Rigel Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Baker Bros. Advisors sold 104,161 Rigel Pharmaceuticals shares in Q3 2018, an estimated $2.95M.
  • Baker Bros. Advisors first reported a position in Rigel Pharmaceuticals in Q3 2013 and held it in 14 quarters.
  • Baker Bros. Advisors's Rigel Pharmaceuticals position peaked at $9.8M in Q4 2017.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.